Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus ZEGERID OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus ZEGERID OTC.
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM vs ZEGERID OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).
None Documented
None Documented
Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation).
Terminal half-life approximately 1.5-2 hours (0.5-1 hour in children); due to short half-life, acid suppression duration is prolonged via irreversible proton pump inhibition
Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal.
Renal (80% as metabolites) and fecal (20%)
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor